Study #2017-0998
A phase II study of nivolumab combined with ipilimumab for patients with advanced rare genitourinary tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Ipilimumab, Nivolumab
Description
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendocrine differentiation. Given preliminary results, the study is being tested in additional patients with bladder or upper tract carcinoma with variant histology at this time while the adrenocortical carcinoma, other rare genitourinary malignancies arms have closed to accrual -The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer, Non-adenocarcinoma Prostate Cancer, Refractory Germ-cell, High Grade Neuroendocrine Carcinoma/small Cell Carcinoma
Study phase:
Phase II
Physician name:
Matthew Campbell
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-939-4993
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.